questionText: To ask the Secretary of State for Health and Social Care, whether she has had discussions with (a) NICE and (b) Bristol Myers Squibb on restarting the NICE appraisals process for luspatercept (Reblozyl).
answerText: Departmental officials regularly discuss a range of issues with colleagues in the National Institute for Health and Care Excellence (NICE), including on access to medicines such as luspatercept (Reblozyl). The Department has had no discussions with Bristo...
heading: Luspatercept: Licensing